GW RhythmX has announced the formal availability of its RhythmX Pulse Precision Care AI application on Microsoft Marketplace, allowing enterprise healthcare organizations to deploy the platform through their existing Microsoft cloud environment. The launch is intended to simplify adoption for health systems already using Microsoft Dragon Copilot by eliminating the need for a separate implementation process.
Unlike ambient documentation tools that primarily summarize clinical conversations, RhythmX Pulse analyzes live encounter dialogue alongside a patient’s medical history, clinical guidelines, social determinants, payer requirements, and formulary information. The platform delivers point-of-care recommendations while the consultation is still underway, enabling clinicians to identify documentation improvements, care gaps, and Hierarchical Condition Category (HCC) coding opportunities before the patient visit concludes.
Within the integrated workflow, the platform continuously validates information captured during the encounter. Its capabilities include real-time synthesis of electronic health record data, identification of documentation opportunities, formulary-aware medication recommendations based on payer requirements, and HCC coding suggestions designed to support appropriate risk adjustment and reimbursement. Physicians remain responsible for every recommendation and can accept, modify, or dismiss prompts as needed.
Commenting on the launch, Deepthi Bathina, founder and CEO of GW RhythmX, said, “Clinical AI is more than summarization or guideline lookups. Now Dragon Copilot users can get the validated and hyper-personalized guidance they need to deliver frontier precision care in every encounter.” Bathina added, “Clinicians get a clear next best action instead of just a summary or generic guidance.”
GW RhythmX was formed through the merger of Get Well and RhythmX AI and operates within the SymphonyAI Group. According to the company, the combined platform is deployed across more than 150 health systems, serving over 85 million patients, including 8 million U.S. military veterans.
The company stated that its technology is supported by more than 170,000 physician-reviewed clinical validations and longitudinal data covering 300 million patients. Future development plans include extending AI-driven recommendations across pre-visit preparation, real-time clinical guidance, care-team coordination, and long-term patient management throughout the care continuum.
Click here for the original news story.
